VIDEO: Strategic sequencing of targeted therapies key in cholangiocarcinoma

Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

They've been a difference maker, honestly, like I mentioned, depending again on the alteration, I mean the FGFR2 spaces where there's been the most impact. So if you have intentional strategic sequencing of these agents, I've had patients who started with pemigatinib in 2020. Our progression went to futibatinib, our progression went to the RLY study, and so and I hear three, four years later. So if you can intentionally and strategically sequence these agents, you can really get three, four years of mileage out of these targeted therapies. Again, this is the FGFR2 space where there's been the most impact. But that's an example of how impactful targeted therapies have been in this disease. The hope is that we can do the same or at least develop drugs for some of the other targets, so that we can really prolong the survival of our patient.